🇺🇸 FDA
Patent

US 11274149

Anti-CD100 antibodies and methods for using the same

granted A61KA61K2039/505A61K38/1774

Quick answer

US patent 11274149 (Anti-CD100 antibodies and methods for using the same) held by VACCINEX, INC. expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
VACCINEX, INC.
Grant date
Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2039/505, A61K38/1774, A61K39/0001, A61K39/3955